C18
Conditions
Interventions
Group 1: Patients undergoing hemicolectomy, total mesorectal excision or sigma resection due to colorectal cancer in curative intention. Patients undergo standard of care treatment and will not be tre
Sponsors
Universitätsklinikum Augsburg, II Medizinische Klinik
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • Age =18 years • Diagnosed with previously untreated or neo-adjuvantly-treated-non-responsive (according to RECIST criteria) colorectal cancer with an indication for hemicolectomy, total mesorectal excision or sigma resection • Size of the tumor to be resected = 2 cm
Exclusion criteria
Exclusion criteria: • Medical or psychological impairments or legal restrictions resulting in reduced capability to give informed consent • Presence of a histopathological finding that does not confirm the tumor diagnosis assumed at the time of enrollment • If the Pathologist determines that the integrity of the vascular system of the resected tissue has been compromised (e.g. through surgery or intraoperative biopsy for rapid histopathological workup) rendering perfusion impossible, the patient will be excluded • If histopathological evaluation–either before (frozen section) and/or after library perfusion– reveals a tumor remission after systemic neoadjuvant cancer therapy, the patient will be excluded from the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility of the procedure to identify specific phage vector capsid-displayed peptides targeting human tumors ex vivo, measured by identification of at least one clone that is significantly enriched in tumor tissue compared to healthy tissue. | — |
Secondary
| Measure | Time frame |
|---|---|
| Identification of phage vector-displayed peptides specifically targeting colorectal cancer tumors upon ex vivo perfusion | — |
Countries
Germany
Contacts
Public ContactMartin Trepel
Universitätsklinikum Augsburg, II Medizinische Klinik
Outcome results
None listed